liminal biosciences inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel treatments for patients suffering from diseases that have unmet medical needs. it operates through two segments, small molecule therapeutics and plasma derived therapeutics. the small molecule therapeutics segment's lead product candidate is fezagepras (pbi-4050) for the treatment of idiopathic pulmonary fibrosis, respiratory diseases, and alstrã¶m syndrome. the plasma derived therapeutics segment provides plasma protein purification system, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. it also engages in developing ryplazim for the treatment of congenital plasminogen deficiency. the company operates in canada, the united kingdom, and the united states. the company was formerly known as prometic life sciences inc. and changed its name to liminal biosciences inc. in october
Company profile
Ticker
LMNL
Exchange
Website
CEO
Kenneth Galbraith
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ProMetic Life Sciences Inc
SEC CIK
Corporate docs
LMNL stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
6 Oct 23
EFFECT
Notice of effectiveness
27 Sep 23
EFFECT
Notice of effectiveness
27 Sep 23
EFFECT
Notice of effectiveness
27 Sep 23
POS AM
Prospectus update (post-effective amendment)
26 Sep 23
25-NSE
Exchange delisting
26 Sep 23
POS AM
Prospectus update (post-effective amendment)
26 Sep 23
POS AM
Prospectus update (post-effective amendment)
26 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Sep 23
6-K
Material Change Report
26 Sep 23
Latest ownership filings
SC 13D/A
Thomvest Asset Management Ltd.
27 Sep 23
SC 13D/A
Thomvest Asset Management Ltd.
13 Jul 23
SC 13D/A
Thomvest Asset Management Ltd.
5 Apr 23
SC 13G/A
Consonance Capital Management LP
17 Feb 21
SC 13G/A
Consonance Capital Management LP
16 Feb 21
SC 13D/A
Thomvest Asset Management Ltd.
25 Nov 20
SC 13D
Thomvest Asset Management Ltd.
6 Nov 20
SC 13G
Beneficial ownership report
14 Feb 20
SC 13G
Liminal BioSciences Inc.
13 Dec 19
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
77.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 2 |
Closed positions | 1 |
Increased positions | 2 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 95.05 mm |
Total shares | 2.40 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Thomvest Asset Management | 2.38 mm | $8.62 mm |
National Bank of Canada | 9.85 k | $61.08 mm |
MS Morgan Stanley | 1.71 k | $10.71 mm |
RY Royal Bank Of Canada | 1.04 k | $7.00 mm |
UBS UBS Group AG - Registered Shares | 715.00 | $4.49 mm |
Estabrook Capital Management | 500.00 | $3.14 mm |
Tanaka Capital Management | 1.00 | $0.00 |
Proequities | 0.00 | $0.00 |